A Phase I, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of Ceftazidime-Avibactam Administered as Single and Repeated Intravenous Doses in Healthy Chinese Subjects

Trial Profile

A Phase I, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of Ceftazidime-Avibactam Administered as Single and Repeated Intravenous Doses in Healthy Chinese Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 09 Dec 2015

At a glance

  • Drugs Avibactam/ceftazidime (Primary)
  • Indications Gram-negative infections; Intra-abdominal infections; Nosocomial infections; Urinary tract infections
  • Focus Adverse reactions
  • Sponsors AstraZeneca
  • Most Recent Events

    • 09 Dec 2015 Results published in the Clinical Drug Investigation
    • 13 Jan 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 01 Oct 2013 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top